Advice

following a full submission assessed under the ultra-orphan medicine process:

crizotinib (Xalkori®) is accepted for use within NHSScotland.

Indication under review: treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).

In a small, single arm, open-label, phase I study of patients with advanced ROS1-positive NSCLC, treatment with crizotinib resulted in an objective response in 70% of patients.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Download full details161KB (PDF)

Download

Medicine details

Medicine name:
crizotinib (Xalkori)
SMC ID:
1329/18
Indication:
Treatment of adults with ROS1-positive advanced non-small cell lung cancer.
Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Accepted
Date advice published:
11 June 2018